Neonatal hyperglycaemia and abnormal development of the pancreas

Best Practice and Research in Clinical Endocrinology and Metabolism

Volumn 22, Issue 1, 2008, Pages 17-40

  Flechtner, Isabelle ^a   Vaxillaire, Martine ^b   Cavé, Hélène ^c   Scharfmann, Raphael ^d   Froguel, Philippe ^e   Polak, Michel ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b CNRS   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d INSERM   (France)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

cell function; diabetes mellitus genes; genetic mechanisms; imprinting; insulin secretion; insulin therapy; kir6.2; neonatal diabetes mellitus; newborns; pancreatic insufficiency; potassium channel; SUR1

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C8; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; BUSULFAN; CHROMOSOME PROTEIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLIBENCLAMIDE; GLUCOKINASE; GLUCOSE; GLUTAMATE DECARBOXYLASE; INITIATION FACTOR 2; INITIATION FACTOR 2 KINASE 3; INSULIN; INSULIN GLARGINE; INSULIN PROMOTER FACTOR 1; INSULIN ZINC SUSPENSION; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; ISOPHANE INSULIN; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNJ11; SULFONYLUREA DERIVATIVE; SULFONYLUREA RECEPTOR 1; THYMOCYTE ANTIBODY; TOLBUTAMIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PTF1A; UNCLASSIFIED DRUG;

AUTOSOMAL RECESSIVE DISORDER; BINDING AFFINITY; CALORIC INTAKE; CHROMOSOME 6Q; CHROMOSOME ABERRATION; CLINICAL FEATURE; CONTINUOUS INFUSION; DIABETES MELLITUS; DIARRHEA; DRUG BINDING SITE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE MUTATION; GENETIC COUNSELING; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; GROWTH RETARDATION; HETEROZYGOSITY; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INTRAUTERINE GROWTH RETARDATION; IPEX SYNDROME; MATURITY ONSET DIABETES MELLITUS; MOLECULAR GENETICS; NEWBORN DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS DISEASE; PANCREAS MALFORMATION; PHARMACOGENOMICS; RELAPSE; REMISSION; REVIEW; SKIN DISEASE; UNSPECIFIED SIDE EFFECT; WOLCOTT RALLISON SYNDROME;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 6; DIABETES MELLITUS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENETIC COUNSELING; HUMANS; HYPERGLYCEMIA; INFANT; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; MALE; PANCREAS; POTASSIUM CHANNELS, INWARDLY RECTIFYING;

EID: 38949137790     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2007.08.003     Document Type: Review

References (95)

1. Von Mühlendahl K.E., and Herkenhoff H. Long-term course of neonatal diabetes. N Engl J Med 333 (1995) 704-708
2. Polak M., and Shield J. Neonatal and very-early-onset diabetes mellitus. Semin Neonatol 9 1 (2004) 59-65
3. Ferguson A.W., and Milner R.D. Transient neonatal diabetes mellitus in sibs. Arch Dis Child 45 (1970) 80-83
4. Fösel S. Transient and permanent neonatal diabetes. Eur J Pediatr 154 (1995) 944-948
5. Shield J.P., and Baum J.D. Transient neonatal diabetes and later onset diabetes: a case of inherited insulin resistance. Arch Dis Child 72 (1995) 56-57
6. Metz C., Cave H., Bertrand A.M., et al. Neonatal Diabetes Mellitus: chromosomal analysis in transient and permanent cases. J Pediatr 141 (2002) 483-489
7. Temple I.K., Gardner R.J., MacKay D.J., Barber J.C., Robinson D.O., and Shield J.P. Transient neonatal diabetes: widening the understanding of the etiopathogenesis of diabetes. Diabetes 49 (2000) 1359-1366
8. Shield J.P., Temple I.K., Sabin M., et al. An assessment of pancreatic endocrine function and insulin sensitivity in patients with transient neonatal diabetes in remission. Arch Dis Child Fetal Neonatal Ed 89 (2004) F341-F343
9. Marquis E., Le Monnier de Gouville I., Bouvattier C., et al. HLA-DRB1 and DQB1 genotypes in patients with insulin-dependent neonatal diabetes mellitus. A study of 13 cases. Tissue Antigens 56 (2000) 217-222
10. Iafusco D., Stazi M.A., Cotichini R., et al. Permanent diabetes mellitus in the first year of life. Diabetologia 45 (2002 Jun) 798-804
11. Temple I.K., James R.S., Crolla J.A., et al. An imprinted gene(s) for diabetes?. Nat Genet. 9 (1995) 110-112
12. Christian S.L., Rich B.H., Loebl C., et al. Significance of genetic testing for paternal uniparental disomy of chromosome 6 in neonatal diabetes mellitus. J Pediatr 134 (1999) 42-46
13. Cave H., Polak M., Drunat S., Denamur E., and Czernichow P. Refinement of the 6q chromosomal region implicated in transient neonatal diabetes. Diabetes 49 (2000) 108-113
14. Temple I.K., Gardner R.J., Robinson D.O., et al. Further evidence for an imprinted gene for neonatal diabetes localized to chromosome 6q22-23. Human Mol Genet 5 (1996) 1117-1121
15. Gardner R.J., Mackay D.J., Mungall A.J., et al. An imprinted locus associated with transient neonatal diabetes mellitus. Hum Mol Genet 9 (2000) 589-596
16. Arima T., Drewell R.A., Arney K.L., et al. A conserved imprinting control region at the HYMAI/ZAC domain is implicated in transient neonatal diabetes mellitus. Hum Mol Genet 10 (2001) 1475-1483
17. Ma D., Shield J.P., Dean W., et al. Impaired glucose homeostasis in transgenic mice expressing the human transient neonatal diabetes mellitus locus, TNDM. J Clin Invest 114 (2004) 339-348
18. Mackay D.J., Boonen S.E., Clayton-Smith J., et al. A maternal hypomethylation syndrome presenting as transient neonatal diabetes mellitus. Hum Genet. 120 (2006) 262-269
19. Bryan J., Crane A., Vila-Carriles W., et al. Insulin secretagogues, sulfonylurea receptors and K(ATP) channels. Curr Pharm Des 11 21 (2005) 2699-2716
20. Inagaki N., Gonoi T., Clement J.P., et al. A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels. Neuron 16 5 (1996) 1011-1017
21. Isomoto S., Kondo C., Yamada M., et al. A novel sulfonylurea receptor forms with BIR (Kir6.2) a smooth muscle type ATP-sensitive K+ channel. J Biol Chem 271 40 (1996) 24321-24324
22. Inagaki N., Gonoi T., Clement J.P., et al. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 270 5239 (1995) 1166-1170
23. Gopel S.O., Kanno T., Barg S., et al. Regulation of glucagon release in mouse -cells by KATP channels and inactivation of TTX-sensitive Na+ channels. J Physiol 528 Pt 3 (2000) 509-520
24. Gopel S.O., Kanno T., Barg S., et al. Patch-clamp characterisation of somatostatin-secreting -cells in intact mouse pancreatic islets. J Physiol 528 Pt 3 (2000) 497-507
25. Gribble F.M., Williams L., Simpson A.K., et al. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 52 5 (2003) 1147-1154
26. Aguilar-Bryan L., Nichols C.G., Wechsler S.W., et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 268 5209 (1995) 423-426
27. Gloyn A.L., Pearson E.R., Antcliff J.F., et al. Activating mutations in the gene encoding the ATP-sensitive potassium channel subunit Kir6.2 gene are associated and permanent neonatal diabetes. N Engl J Med 350 (2004) 1838-1849
28. Winarto A., Miki T., Seino S., et al. Morphological changes in pancreatic islets of KATP channel-deficient mice: the involvement of KATP channels in the survival of insulin cells and the maintenance of islet architecture. Arch Histol Cytol 64 1 (2001) 59-67
29. Miki T., Iwanaga T., Nagashima K., et al. Roles of ATP-sensitive K+ channels in cell survival and differentiation in the endocrine pancreas. Diabetes 50 Suppl. 1 (2001) S48-S51
30. Seino S., and Miki T. Gene targeting approach to clarification of ion channel function: studies of Kir6.x null mice. J Physiol 554 Pt 2 (2004) 295-300
31. Dunn-Meynell A.A., Rawson N.E., and Levin B.E. Distribution and phenotype of neurons containing the ATP-sensitive K+ channel in rat brain. Brain Res 814 1-2 (1998) 41-54
32. Yamada K., and Inagaki N. Neuroprotection by KATP channels. J Mol Cell Cardiol 38 6 (2005) 945-949
33. Yamada K., and Inagaki N. ATP-sensitive K(+) channels in the brain: sensors of hypoxic conditions. News Physiol Sci 17 (2002) 127-130
34. Miki T., Liss B., Minami K., et al. ATP-sensitive K+ channels in the hypothalamus are essential for the maintenance of glucose homeostasis. Nat Neurosci 4 5 (2001) 507-512
35. Deacon R.M., Brook R.C., Meyer D., et al. Behavioral phenotyping of mice lacking the K ATP channel subunit Kir6.2. Physiol Behav 87 4 (2006) 723-733
36. Gong B., Legault D., Miki T., et al. KATP channels depress force by reducing action potential amplitude in mouse EDL and soleus muscle. Am J Physiol Cell Physiol 285 6 (2003) C1464-C1474
37. Zingman L.V., Hodgson D.M., Bast P.H., et al. Kir6.2 is required for adaptation to stress. Proc Natl Acad Sci U S A 99 20 (2002) 13278-13283
38. Quayle J.M., Nelson M.T., and Standen N.B. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 77 4 (1997) 1165-1232
39. Koster J.C., Marshall B.A., Ensorn, et al. Targeted overactivity of beta cell K(ATP) channels induces profound neonatal diabetes. Cell 100 6 (2000) 645-654
40. Gloyn A.L., Weedon M.N., Owen K.R., et al. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 52 2 (2003) 568-572
41. Florez J.C., Burtt N., de Bakker P.I., et al. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 53 5 (2004) 1360-1368
42. Tschritter O., Stumvoll M., Machicao F., et al. The prevalent Glu23Lys polymorphism in the potassium inward rectifier 6.2 (KIR6.2) gene is associated with impaired glucagon suppression in response to hyperglycemia. Diabetes 51 9 (2002) 2854-2860
43. Vaxillaire M., Populaire C., Busiah K., et al. Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes 53 (2004) 2719-2722
44. Massa O., Iafusco D., D'amato E., et al. KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes. Hum Mutat 25 1 (2005) 22-27
45. Gloyn A.L., Reimann F., Girard C., et al. Relapsing diabetes can result from moderately activating mutations in KCNJ11. Hum Mol Genet 14 (2005) 925-934
46. Gloyn A.L., Cummines E.A., Edehill E.L., et al. Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 Gene encoding the Kir6.2 subunit of the beta-cell potassium adenosine triphosphate channel. J Clin Endocrinol Metab 89 8 (2004) 3932-3935
47. Proks P., Antcliff J.F., Lippiat J., et al. Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc Natl Acad Sci U S A 101 50 (2004) 17539-17544
48. Antcliff J.F., Haider S., Proks P., et al. Functional analysis of a structural model of the ATP-binding site of the KATP channel Kir6.2 subunit. Embo J 24 2 (2005) 229-239
49. John S.A., Weiss I.N., Xiel H., et al. Molecular mechanism for ATP-dependent closure of the K+ channel Kir6.2. J Physiol 552 Pt 1 (2003) 23-34
50. Ribalet B., John S.A., and Weiss J.N. Molecular basis for Kir6.2 channel inhibition by adenine nucleotides. Biophys J 84 1 (2003) 266-276
51. Colombo C., et al. Transient neonatal diabetes mellitus is associated with a recurrent (R201H) KCNJ11 (KIR6.2) mutation. Diabetologia 48 11 (2005) 2439-2441
52. Tammaro P., Proks P., and Ashcroft F.M. Functional effects of naturally occurring KCNJ11 mutations causing neonatal diabetes on cloned cardiac KATP channels. J Physiol 571 Pt 1 (2006) 3-14
53. Gribble F.M., Tucker S.J., Seino S., et al. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels. Diabetes 47 9 (1998) 1412-1418
54. Babenko A.P., Polak M., Cavé H., et al. Activating Mutations in ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 355 (2006) 456-466
55. Stanik J., Gasperikova D., Paskova M., et al. Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. J Clin Endocrinol Metab 92 4 (2007) 1276-1282
56. Flanagan S.E., Patch A.M., Mackay D.J., et al. Mutations in KATP channel genes cause transient neonatal diabetes and permanent diabetes in childhood and adulthood. Diabetes 56 (2007) 1930-1937
57. Vaxillaire M., Dechalime A., Busiah K., et al. New ABCC8 mutations in relapsing neonatal diabetes and clinical features. Diabetes 56 (2007) 1737-1741
58. Jonsson J., Carlsson L., Edlund T., and Edlund H. Insulin-promoter-factor 1 is required for pancreas development in mice. Nature 371 (1994) 606-609
59. Vaulont S., Vasseur-Cognet M., and Kahn A. Glucose regulation of gene transcription. J Biol Chem 275 (2000) 31555-31558
60. Stoffers D.A., Zinkin N.T., Stanojevic V., Clarke W.L., and Habener J.F. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF-1 coding sequence. Nat Genet 15 (1997) 106-110
61. Stoffers D.A., Stanojevic V., and Habener J.F. Insulin Promoter Factor-1 gene mutation linked to early onset type 2 diabetes mellitus directs expression of dominant negative isoprotein. J Clin Invest 102 (1998) 232-241
62. Hoveyda N., Shield J.P., Garrett C., et al. Neonatal diabetes mellitus and cerebellar hypoplasia/agenesis: report of a new recessive syndrome. J Med Genet 36 (1999) 700-704
63. Sellick G.S., Barker K.T., and Stolte-Dijkstra I. et al Mutations in PTF1A cause pancreatic and cerebellar agenesis. Nat Genet 36 (2004) 1301-1305
64. Ashraf A., Abdullatif H., Hardin W., and Moates J.M. Unusual case of neonatal diabetes mellitus due to congenital pancreas agenesis. Pediatric diabetes 6 (2005) 239-243
65. Velho G., and Froguel P. Genetic, metabolic and clinical characteristics of maturity onset diabetes of the young. Eur J Endocrinol 138 (1998) 233-239
66. Njolstad P.R., Sovik O., Cuesta-Munoz A., et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med 344 (2001) 1588-1592
67. Gloyn A.L., Ellard S., Shield J.P., et al. Complete glucokinase deficiency is not a common cause of permanent neonatal diabetes. Diabetologia 45 (2002) 290
68. Vaxillaire M., Samson C., Cave H., Metz C., Froguel P., and Polak M. Glucokinase gene mutations are not a common cause of permanent neonatal diabetes in France. Diabetologia 45 (2002) 454-455
69. Peake J.E., McCrossin R.B., Byrne G., and Shepherd R. X-linked immune dysregulation, neonatal insulin dependent diabetes, and intractable diarrhoea. Arch Dis Child Fetal Neonatal Ed 74 (1996) F195-F199
70. Roberts J., and Searle J. Neonatal diabetes mellitus associated with severe diarrhoea, hyperimmunoglobulin E syndrome, and absence of islets of Langerhans. Pediat Pathol Lab Med 15 (1995) 477-483
71. Satake N., Nakanishi M., Okano M., et al. A Japanese family of X-linked auto-imune enteropathy with haemolytic anaemia and polyendocrinopathy. Eur J Pediat 152 (1993) 313-315
72. Baud O., Goulet O., Canioni D., et al. Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. New Eng J Med 344 (2001) 1758-1762
73. Bennett C., Christie J., Ramsdell F., et al. The immune dysregulation, poly-endocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27 (2001) 20-21
74. Brunkow M.E., Jeffery E.W., Hjerrild K.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27 (2001) 68-73
75. Wolcott C.D., and Rallison M.L. Infancy-onset diabetes mellitus and multiple epiphyseal dysplasia. J Pediatr 80 (1972) 292-297
76. Delepine M., Nicolino M., Barrett T., Golamaully M., Lathrop G.M., and Julier C. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet 25 (2000) 406-409
77. Harding H.P., Zhang Y., Bertolotti A., Zeng H., and Ron D. Perk is essential for translational regulation and cell survival during unfolded protein response. Mol Cell 5 (2000) 897-904
78. Zhang W., Feng D., Li Y., et al. PERK EIF2AK3 control pancreatic beta cell differentiation and proliferation is required for postnatal glucose homeostasis. Cell Metabolism 4 (2006) 491-497
79. Harding H.P., Zeng H., Zhang Y., et al. Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival. Mol Cell 7 (2001) 1153-1163
80. Christen H.J., Hanefeld F., Duley J.A., and Simmonds H.A. Distinct neurological syndrome in two brothers with hyperuricaemia. Lancet 340 (1992) 1167-1168
81. Yorifuji T., Matsumura M., Okuno T., et al. Hereditary pancreatic hypoplasia, diabetes mellitus, and congenital heart disease: a new syndrome?. J Med Genet 31 (1994) 331-333
82. Senee V., Chelala C., Duchatelet S., et al. Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism. Nat Genet 38 (2006) 682-687
83. Otonkoski T., Roivainen M., Vaaral O., et al. Neonatal type 1 diabetes associated with maternal echovirus 6 infection: a case report. Diabetologia 43 (2000) 1235-1238
84. Henquin J.C. Pathways in beta-cell stimulus-secretion coupling as targets for therapeutic insulin secretagogues. Diabetes 53 Suppl. 3 (2004) S48-S58
85. Gribble F.M., and Ashcroft F.M. Differential sensitivity of beta-cell and extrapancreatic K(ATP) channels to gliclazide. Diabetologia 42 7 (1999) 845-848
86. Gribble F.M., Tucker S.J., and Ashcroft F.M. The interaction of nucleotides with the tolbutamide block of cloned ATP-sensitive K+ channel currents expressed in Xenopus oocytes: a reinterpretation. J Physiol 504 Pt 1 (1997) 35-45
87. Nagashima K., Takahashi A., Ikeda H., et al. Sulfonylurea and non-sulfonylurea hypoglycemic agents: pharmachological properties and tissue selectivity. Diabetes Res Clin Pract 66 Suppl. 1 (2004) S75-S78
88. Zung A., Glaser B., Nimri R., et al. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab 89 11 (2004) 5504-5507
89. Codner E., Flanagan S., Ellard S., et al. High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. Diabetes Care 28 3 (2005) 758-759
90. Sagen J.V., Raeder H., Hathout E., et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 53 (2004) 2713-2718
91. Klupa T., Edghill E.L., Nazim L., et al. The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation. Diabetologia 48 5 (2005) 1029-1031
92. Pearson E.R., Flechtner I., Njolstad P.R., et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355 (2006) 467-477
93. Maedler K., Carr R.D., Bosco D., et al. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 90 1 (2005) 501-506
94. Rustenbeck I., Krautheim A., Jorns A., et al. Beta-cell toxicity of ATP-sensitive K+ channel-blocking insulin secretagogues. Biochem Pharmacol 67 9 (2004) 1733-1741
95. Mitamura R., Kimura H., Murakami Y., Nagaya K., Makita Y., and Okuno A. Ultralente insulin treatment of transient neonatal diabetes mellitus. J Pediatr 128 (1996) 268-270